Peter Kleinhenz is a Managing Director of CID Capital. He has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for virtually all of his professional career and has provided leadership for new venture formation in the life sciences sector for over 20 years. Peter leads the firm's investments in life sciences.

Peter is a director or observer for the following CID investments: Axiomed Spine Corporation, a company focusing on the development of spinal implant solutions that will restore the native mobility of the spine; Celleration, Inc. a medical device company focused on wound healing using low frequency ultrasonic energy; EKOS Corporation, a company developing and commercializing novel high technology ultrasound-enhanced micro-catheters for dissolving blood clots in the brain or in the peripheral arteries in the legs; MedVantx, developer of the first fully integrated, consumer centric pharmaceutical delivery channel primarily for generics and OTC drugs; and RedPath Integrated Pathology, a Pittsburgh based molecular diagnostic and anatomic pathology service company.

Peter has been active in economic development issues on the local and state level for over 20 years and currently serves on the Executive Committee and as Treasurer of BioOhio, Ohio's life science initiative, and as a member of BioOhio's Central Ohio regional efforts. He is a founding member of the Midwest Healthcare Investment Network and serves as a member of MHIN's Board of Directors. He is chairman of MHIN's annual MidAmerica Healthcare Venture Forum. He is on the Advisory Board for the BioGenerator at the Nidus Center in St. Louis, Missouri and the Columbus Technology council's TechColumbus program, Columbus, OH.

Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization for Battelle Memorial Institute and as an independent consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups, assisting in business management and finance. Peter was CEO of Progenics, which he sold to Fitch, Inc., an international product design and development firm, in 1997. Progenics was engaged in product development and pilot manufacturing services for medical products. He served in a variety of senior executive positions at Neoprobe Corporation, a biotech device company focused on cancer diagnostics and therapeutics. The positions included CFO, Vice President of Manufacturing, and Vice President of Strategic Planning and Business Development. Peter received an MBA from The Weatherhead School of Management at Case Western Reserve University, a bachelor's degree in history from Loyola University of Chicago, and is a Certified Public Accountant licensed in Ohio.

Peter received an MBA from The Weatherhead School of Management at Case Western Reserve University, a bachelor's degree in history from Loyola University of Chicago, and is a Certified Public Accountant licensed in Ohio.